Displaying 26 (all) recruiting clinical trials.
-
NVL-520-01: A Phase 1/2 study of the highly selective ROS1 inhibitor NUV-520 in patients with advanced NSCLC and other solid tumors (ARROS-1).
You can participate in this study if you are diagnosed with advanced non-small cell lung cancer, and other advanced solid cancers. The purpose of this ...
Phase
Interventional
-
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers
This study is testing a new cancer treatment called MK-2870 to see if it has few side effects and works well for patients with certain ...Phase
Interventional
-
EVEREST-2: A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B694 an Autologous Logic-gated Tmod CAR T in Heterozygous HLA-A*02 Adults with Recurrent Unresectable Locally Advanced or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
econditioning lymphodepletion) for different cancers that express mesothelin (MSLN). First, the study team will test it on a small number of patients to see if ...
Phase
Interventional
-
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia
This study is designed to test how effective a new drug called AZD0486 (BITE for CD19) is for patients relapsed/refractory B-cell acute lymphoblastic leukemia ...
Phase
Interventional
-
A PHASE 1B/2 MULTICENTER OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd) A B7-H3 ANTIBODY-DRUG CONJUGATE (ADC) IN COMBINATION WITH ATEZOLIZUMAB WITH OR WITHOUT CARBOPLATIN AS FIRST-LINE INDUCTION OR MAINTENANCE IN SUBJECTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) (IDeate-Lung03)
This global study is designed to test how safe and effective the drug I-DXd is when combined with atezolizumab, with or without carboplatin. The treatment ...
Phase
Interventional
-
A Phase 1/2 First-Time-in-Human open-label multicenter dose escalation and expansion study of the oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors (SYLVER)
This study will test how well the oral WRN inhibitor GSK4418959 works and whether it has few side effects, both by itself and with dostarlimab ...
Phase
Interventional
-
A Platform Study of RAS(ON) Inhibitor Combinations in Patients with RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
This study is designed to test how effective a new drug called AZD0486 (BITE for CD19) is for patients relapsed/refractory B-cell acute lymphoblastic leukemia ...
Phase
Interventional
-
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
This study is testing the effectiveness of a new drug, MRTX1719, in patients with advanced solid tumors that have a specific genetic change called MTAP ...
Phase
Interventional
-
A Phase 1/2 Multicenter Open-Label Study to Evaluate the Safety Tolerability and Preliminary Antitumor Activity of TNG462 in Combination with Other Agents in Patients with Pancreatic or Non-Small Cell Lung Cancer with MTAP Loss and RAS Mutation
This Phase 1/2 study will determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236 or RMC-9805 ...Phase
Interventional
-
A Phase 1/2 Multicenter Open-Label Study to Evaluate the Safety Tolerability and Preliminary Antitumor Activity of TNG456 Monotherapy and in Combination with Abemaciclib in Patients with Solid Tumors with MTAP Loss
This study is testing a new medicine, TNG456, alone and with another medicine called Abemaciclib, to find the dose that works well and has fewer ...
Phase
Interventional
